The Future of Medical Records – FHIR

As medical care becomes increasingly sophisticated, the successful transfer and utilization of patient records is critical for providing the best outcomes. The Fast Healthcare Interoperability Resource (FHIR), developed by the nonprofit group Health Level 7 International (HL7), is the latest standard for such data. FHIR seeks to transform the way patient data is used by giving everyone from doctors to developers the opportunity to view and build on it in unprecedented ways. Before FHIR, standards for sharing patient data could roughly be compared to PDFs. Health care providers receiving a report from another doctor could see the doctor’s notation, but Read More …

The Differences between SBIR and STTR Cheat Sheet

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs both provide Small Business Administration (SBA) grants to small businesses for research. The two programs share the same three phases, with separate federal contracts awarded for Phases I and II. Phase I is innovation and research, where the scientific merit and commercial viability of an innovation is studied.  Phase II focuses on the innovation’s development, demonstration and delivery. Phase III involves preparation for commercial rollout and is funded by outside sources rather than the SBA. While the two programs share many similarities, they have some important differences Read More …

Emory Female Inventors Revisited

The Emory community is proud to have some of the most cutting-edge research teams led by women. Female scientists at Emory are responsible for a variety of innovative discoveries in biomedical sciences and technology. Some of their inventions have had profound positive impact on the scientific community and society as a whole. In this article, we are honoring five of Emory’s female inventors and their work. Cassandra Quave is an Assistant Professor of Dermatology at the School of Medicine and the Center for the Study of Human Health. She is a medical ethnobotanist, studying the medicinal properties of novel plant Read More …

Clinical Trials 101

Any time a new drug appears on the market, the final product is a result of years of research and testing. The time from conception to FDA approval for medications takes 12 years on average. An important and time-consuming aspect of this process are clinical trials. By testing a drug on gradually increasing numbers of patients and volunteers, researchers are able verify that it is both safe and effective in treating the disease or condition. Only when the first three steps of this process are complete can the drug be approved and commercially distributed. Phase 1 is the shortest of Read More …

Introduction to Artificial Intelligence and Healthcare

The healthcare industry generates a lot of data. X-rays, pathology slides, patient vitals, clinical trial information; we have mountains of information accessible at the touch of a button. But it’s costly and time-inefficient for humans to manually pour over it. So what do we do with all of this data? The field of intelligence (AI) allows not only to let us analyze all our data, but to find subtle and complex patterns in them. Machine learning algorithms are particularly responsible for these advancements. Engineers have developed software that’s able to look at a dataset, find relationships between a bunch of Read More …

Faculty as Start-up Founder: One Man’s Experience

Raymond Dingledine, PhD is Emory professor of Pharmacology and co-founder of Emory’s screening facility. His research focuses on the pharmacology of glutamate receptors and the causes of epilepsy. Dingledine’s has received numerous awards such as the ASPET’s Robert R. Ruffolo Career Achievement Award in Pharmacology and election to the National Academy of Medicine. He has published over 200 research papers, served as editor of “Molecular Pharmacology,” and sat on the editorial board of “Molecular Interventions.” Ray is also co-founder of Emory start-up NeurOp. In this interview he shares some of his thoughts and experiences as co-founder of a company. Tell Read More …

Emory Start-ups Continue to Have Impact, Success, and Products to Market

In 2014, OTT published a comprehensive survey of all start-up companies founded on Emory intellectual property. The results proved Emory to be an economic hub in the South, generating not only private and public investment capital, but also job growth and life-saving products. Across the 72 companies surveyed at the time, 1,200 workers had been employed at peak, mostly in the areas of drug development, diagnostic materials, and software-based products. These start-ups cumulatively raised more than a billion dollars in funding and brought 30 different products to market. Now, five years later, OTT has updated its survey, unquestionably demonstrating the Read More …

An Introduction to Investor Pitches

You’ve filled out all the paperwork, organized all your patents, developed your prototypes, and maybe started selling products. Your company has reached the point where if you want to get any further, you’ll need some money. It’s time to pitch to investors. The biggest mistake you can make when developing a business pitch is thinking that what you’re pitching is simply a business or a product. Investors hear of great ideas and promising businesses constantly. A key element that distinguishes one company from the next is the people running it. Try to pitch the team behind the company. A great Read More …

The Small Business Administration: Its Resources and Opportunities

Getting a startup off the ground is a grueling task. What’s harder is working through the process alone. Luckily, the U.S. federal government recognizes the value in entrepreneurship and as such, works to support small companies through various resources offered by the Small Business Administration (SBA). In this article, we will highlight the key resources offered by the SBA broken into four categories. Funding Programs For its funding programs, the SBA mostly acts as a mediator between lenders and small businesses. For instance, interested entrepreneurs can utilize the SBA’s Lender Match service, an online referral tool that connects small businesses Read More …

Business Plan Example

This is the companion post to our introduction to business plans, you can find that post here. Executive Summary MotionBud Inc. designs, manufactures, and markets a practical and portable non-pharmaceutical approach to motion sickness that prioritizes style, comfort, and effectiveness. Our mission is to lead the motion sickness relief market in the development of novel solutions that target the inner ear, our brain’s motion sensor, directly. Our FDA approved device is the first of its kind on a market that traditionally favors OTC drugs and acupressure wristbands. As roughly 50% of the world’s population suffers from motion sickness in some Read More …

Getting Started with a Business Plan

A business plan outlines a company’s goals and the strategies by which it achieves these goals. Typically, a business plan consists of: a) an executive summary, b) a description of products or services, c) industry overview/market analysis, d) marketing and sales strategies, e) operations/execution strategy, f) competitive analysis, g) description of management team, h) financial statement and i) an exit strategy. Below is a high-level description of each of these components. A business plan starts with an executive summary, an overview of the business plan. This operates as a reader on the company and is meant to concisely communicate its Read More …

Corporate Structures for the Newbie

Choosing a corporate structure isn’t just an exercise in paperwork – it determines the company’s tax status, as well as its relationship to potential investors and managers. In this regard, it is one of several key decisions to be made in the early life of your startup. Generally speaking, there are four primary considerations that can guide this decision-making process. These are a) tax requirements, b) access to outside funding, c) level of legal protection, and d) administrative obligations. Below is an outline for a handful of common corporate structures relevant to university-based startups focusing on these elements. C Corporations Read More …

STTR/SBIR Proposal Assistance Resources

In the world of startup funding, resources and donors abound. Securing a piece of this abundance, however, is quite a tricky prospect. Two such funding programs, the STTR (Small Business Technology Transfer Research) and SBIR (Small Business Innovation Research), are operated by the U.S. government agencies such as NIH, DOD and others. These initiatives allot federal research money to small businesses with the intent of funding scientific research directed towards commercialization efforts. This article will dive deeper into the STTR/SBIR application process, highlighting various resources available to researchers who wish to utilize such funding in their own startup efforts. A Read More …

The OTT POC Fund: A Little Goes a Long Way

What’s one of the biggest hurdles to startup success? Finding enough money to start. Seed funding is absolutely critical to getting new technologies on the market. It’s the money that can help give an idea a physical shape, put it on the path to becoming a full-fledged product. The POC fund is a simple idea reflected in its simple acronym: proof of concept. The fund is meant to give Emory inventors enough money to develop their product with as little bureaucratic stalling as possible. By getting funds into the hands of innovators quickly and effectively, and by helping provide follow-up Read More …

From the Director: IP Policy Q&A

Many people are unaware, but most universities, including Emory, have formal intellectual property (IP) policies. At first glance it might seem counterintuitive to the university mission of creating and sharing knowledge, but the policies are written in a way that both encourage scholarly activity and the open exchange of ideas while balancing the potential to commercialize new inventions. What these polices say is that if one happens to make an invention that could end up as a new product then the institution owns the invention – but in return, as part of the deal, the institution fronts various costs associated Read More …

Crowdfunding Your Start-up? Be Wary.

Crowdfunding has been all the rage for years now. Take Ouya or the Pebble Watch, for example, which raised millions of dollars within a matter of weeks. The product-based platforms of Kickstarter or IndieGoGo aren’t even the only ones out there—equity crowdfunding is also becoming a popular method of raising funds among newer startups, even those that already have Series A funding. But it’s important to know crowdfunding isn’t without its drawbacks. Start-ups, especially less established ones, need to be careful before turning to the world wide web for what seems like free money. It isn’t. Money off the Top Read More …

Evolution of an Epidemic: Taming a Killer Virus

AIDS—acquired immunity deficiency syndrome—was named in 1982, at the beginning of the epidemic in the U.S. It was another two years before it was known that human immunodeficiency virus (HIV) was the cause of this strange new disease. Death rates rose steadily and steeply over the next decade. By the mid-1990s, AIDS was the leading cause of death for Americans ages 25 to 44 and more than 250,000 people had died from AIDS or AIDS-related causes. “Some of our most creative people were taken away from us by this terrible disease,” says Emory synthetic chemist Dennis Liotta. “I became increasingly Read More …

Marianne Swanson: The Survivor

Marianne Swanson, a senior staff nurse at Grady Health System’s Ponce Center, was born and raised in Brooklyn, in a close-knit Italian-American family and community. She lost her first husband and two of her three children to AIDS, and she is HIV positive. This is her story: Starting a family: Jeff and I were in a singing group in a Catholic Church, that was where we met. We fell in love and got married in a small Christian church in Brooklyn. We were married for about two years before I got pregnant with our first son, Jonathan. My second son Read More …

Nina Martinez: The HIV Positive Twin

Public health analyst Nina Martinez is 35 years old and has been living with HIV for all but six weeks of her life. Her father was active duty Navy, and she’s a twin. She has HIV while her twin does not. This is her story: How it happened: My twin and I were born 12 weeks early and at that time in the mid-1980s you needed to take a lot of lab work. Because they took labs so often, we were both anemic. We required blood transfusions at 6 weeks old. I was transported to San Francisco and she remained Read More …

Dennis Liotta: The Chemist

Synthetic chemist Dennis Liotta, PhD, Samuel Candler Dobbs Professor at Emory and executive director of the Emory Institute for Drug Development, is the co-developer of an antiretroviral drug that has saved the lives of countless people living with HIV around the world. Starting out: Liotta says he was “genetically coded to be a chemist.” Not only was he naturally drawn to the field, he was able to follow the footsteps of his oldest brother, an organic chemist at Georgia Tech. “Charles was my first scientific role model,” Liotta says. “He is one of the most gifted teachers I’ve ever seen. Read More …